WO1997044062A1 - Utilisation d'agonistes de 5-ht1b/1d dans le traitement de douleurs oculaires - Google Patents

Utilisation d'agonistes de 5-ht1b/1d dans le traitement de douleurs oculaires Download PDF

Info

Publication number
WO1997044062A1
WO1997044062A1 PCT/US1997/005465 US9705465W WO9744062A1 WO 1997044062 A1 WO1997044062 A1 WO 1997044062A1 US 9705465 W US9705465 W US 9705465W WO 9744062 A1 WO9744062 A1 WO 9744062A1
Authority
WO
WIPO (PCT)
Prior art keywords
agonists
agonist
pain
ocular pain
composition
Prior art date
Application number
PCT/US1997/005465
Other languages
English (en)
Inventor
Daniel A. Gamache
Najam Sharif
Original Assignee
Alcon Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories, Inc. filed Critical Alcon Laboratories, Inc.
Priority to AU24342/97A priority Critical patent/AU2434297A/en
Publication of WO1997044062A1 publication Critical patent/WO1997044062A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Definitions

  • the present invention relates to the pharmaceutical treatment of pain.
  • the present invention relates to the pharmaceutical treatment of pain.
  • the present invention relates to the use of 5-HT 1 B/1 D receptor agonists and partial agonists
  • Pain is a perceived nociceptive response to local stimuli in the body. The perception
  • electro-chemical signals are transmitted from the sensory nerve endings to the
  • the cornea is highly innervated with sensory afferents which transmit various parameters
  • ocular pain can result from photorefractive keratotomy (PRK), a vision correcting, surgical
  • PRK photorefractive keratotomy
  • NSAIDs steroidal anti-inflammatory drugs
  • Prostaglandins can modulate pain perception at the level of the central nervous system and
  • Opiates are another class of compounds used to treat pain. Opiates can be any organic compound used to treat pain. Opiates can be any organic compound used to treat pain. Opiates can be any organic compound used to treat pain. Opiates can be any organic compound used to treat pain. Opiates can be any organic compound used to treat pain. Opiates can be any organic compound used to treat pain. Opiates can be any organic compound used to treat pain. Opiates can be any organic compound used to treat pain. Opiates can benzo
  • opiates can be administered systemically, by intravenous injection or oral dosage, or locally, by subcutaneous, intramuscular or
  • Local anesthetics are another class of pain modulators which relieve pain by directly
  • agents have also been suggested for use in treating pain.
  • agents include tricyclic antidepressants such as imipramine and desipramine, alpha-2 adrenergic agonists, serotonin uptake blockers, such as prozac, and other analgesics such as paracetamol, as
  • Serotonin or 5-hydroxytryptamine (“5-HT') is an endogenous peripheral and
  • 5-HT receptors A number of different sub-types of 5-HT receptors have been discovered, based on differential agonist/antagonist sensitivities, second messenger coupling and protein structures. Such sub-types include, for example, 5-HT 1B , 5-HT 1 D , 5-HT 1 ⁇ and 5-HT 2A
  • the 5-HT 1B receptor exists in rodents, while the homolog of this receptor, the
  • 5-HT 1D receptor pharmacologically defined 5-HT 1D receptor, exists in canine, pig and human species
  • the present invention is directed to compositions and methods for treating ocular
  • the present invention is based in part on the finding that compounds which bind to
  • compositions containing 5-HT 1D and/or 5-HT 1B agonists for the
  • the methods of the present invention involve the topical dosage of the compositions described above.
  • One advantage of this therapy is that the inhibition of pain is receptor-
  • ocular tissue avoid the problems of tolerance, addiction and constipation associated with the
  • the present invention is directed to the use of 5-HT 1D and/or 5-HT 1B receptor
  • the 5-HT ] D (“ID”) receptor is found in
  • human tissue such as cerebral arteries and parts of the brain, such as the basal ganglia, raphe
  • the 5-HT 1B (“IB”) receptor thus far, has
  • the IB receptor has been shown to possess similar homology, and thus similar sensitivity, as the ID receptor (Hoyer et al., Pharmacological Reviews, at 167-170).
  • IB receptor agonists will activate ID receptors.
  • the compounds of the present invention are ID agonists, IB agonists or IB/ ID
  • IB agonist refers to a compound which activates a IB
  • ID agonist refers to a compound which activates a ID receptor
  • IB/ ID a compound which activates a ID receptor
  • agonist refers to a compound which activates either a 1 B or a 1 D receptor.
  • Preferred IB/ ID compounds of the present invention are:
  • IB/ID agonist 7-trifluoromethyl-4(4-methyl-l-piperazinyl)- pyrrolo[l,2-a]quinoxaline maleate (CGS-12066A).
  • CGS-12066A 7-trifluoromethyl-4(4-methyl-l-piperazinyl)- pyrrolo[l,2-a]quinoxaline maleate
  • IB/ID agonists of the present invention are available from commercial sources.
  • Drug candidates were tested in a formalin-induced model of ocular pain in the rat.
  • ⁇ g dose of formalin typically yielded about 40-50 blinks in the first minute.
  • the control counts of vehicle animals were compared to the counts of dosed animals and percent
  • the IB/ID agonists of the present invention will be contained in topical compositions,
  • the present invention is particularly directed to the provision of compositions adapted
  • compositions of the present invention are for topical treatment of ophthalmic tissues.
  • ophthalmic compositions of the present invention are provided.
  • inventions will include one or more IB/ID agonists and a pharmaceutically acceptable vehicle
  • the vehicles will generally be
  • Aqueous solutions or suspensions are generally preferred, based on ease of
  • compositions as well as a patient's ability to easily administer such compositions by means of
  • compositions Suspensions may be preferred for IB/ ID agonists which are relatively
  • compositions of the present invention may also include
  • ingredients such as buffers, preservatives, co-solvents and viscosity building
  • An appropriate buffer system e.g., sodium phosphate, sodium acetate or sodium
  • borate may be added to prevent pH drift under storage conditions.
  • Ophthalmic products are typically packaged in multidose form. Preservatives are thus provided.
  • Suitable preservatives include: benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben,
  • Such preservatives are typically employed at a level of from 0.001
  • Some of the compounds of the present invention may have limited solubility in water
  • co-solvents include: polyethoxylated castor oils, Polysorbate 20, 60 and 80; Pluronic®
  • Such co-solvents are typically employed at a level of from
  • Viscosity greater than that of simple aqueous solutions may be desirable to increase
  • Such viscosity building agents include, for example, polyvinyl alcohol, polyvinyl pyrrolidone, methyl cellulose,
  • hydroxypropyl cellulose or other agents known to those skilled in the art. Such agents are
  • the compounds may also be used for treating irritated tissues following ophthalmic
  • the compounds may be used for acute treatment of temporary conditions, or may be
  • the compounds may also be used prophylactically, especially prior
  • compositions of the present invention may be used in treating pain arising from allergens,
  • the compounds of the present invention may be used for the treatment of pain
  • the IB/ID agonists can be individually dosed
  • Patent Nos. 4,939,135 and 5,401,510 Robot et al.
  • the term “pharmaceutically effective amount” refers to that amount of one or more IB/ ID agonists which prevents or alleviates ocular pain.
  • compositions of the present invention are further illustrated by the following
  • the ingredient "IB/ID agonist” denotes a compound of the present invention.
  • IB/ ID agonist 0.01-1.0% Phosphate Buffered Saline 1.0 Hydroxypropyl- ⁇ -cyclodextrin 4.0 Purified water q.s. to 100%

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne des compositions et des procédés de traitement de douleurs oculaires. Cette invention concerne plus particulièrement des compositions ainsi que des procédés d'utilisation d'agonistes de 5-HT1B/1D dans la prévention ou le soulagement de douleurs oculaires.
PCT/US1997/005465 1996-05-23 1997-04-02 Utilisation d'agonistes de 5-ht1b/1d dans le traitement de douleurs oculaires WO1997044062A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU24342/97A AU2434297A (en) 1996-05-23 1997-04-02 The use of 5-ht1b/1d agonists to treat ocular pain

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1822196P 1996-05-23 1996-05-23
US60/018,221 1996-05-23

Publications (1)

Publication Number Publication Date
WO1997044062A1 true WO1997044062A1 (fr) 1997-11-27

Family

ID=21786861

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/005465 WO1997044062A1 (fr) 1996-05-23 1997-04-02 Utilisation d'agonistes de 5-ht1b/1d dans le traitement de douleurs oculaires

Country Status (2)

Country Link
AU (1) AU2434297A (fr)
WO (1) WO1997044062A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999022730A1 (fr) * 1997-10-31 1999-05-14 Vanguard Medica Limited Utilisation de (+)-6-carboxamido-3-methylamino-1,2,3,4-tetrahydrocarbazole pour le traitement de l'hyperalgie
WO2000074649A2 (fr) * 1999-06-03 2000-12-14 Maxim Pharmaceuticals, Inc. Compositions ophtalmiques a base d'histamine et leurs utilisations
WO2001015677A2 (fr) * 1999-08-31 2001-03-08 Alcon Laboratories, Inc. Utilisation d'agonistes de 5-ht1b/1d pour le traitement des douleurs oculaires
EP1410798A2 (fr) * 1999-01-08 2004-04-21 Maxim Pharmaceuticals, Inc. Traitement et prévention des dommages cellulaires induits par des métabolites réactives d'oxygène
EP1536819A2 (fr) * 2002-03-29 2005-06-08 Maxim Pharmaceuticals, Inc. Utilisation de la production de rom et d'inhibiteurs de liberation pour traiter et prevenir des dommages intraoculaires

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252749A (en) * 1991-09-25 1993-10-12 Elf Sanofi Ethers of thienocyclopentanone oximes, their preparation and pharmaceutical compositions containing them
FR2690847A1 (fr) * 1992-05-07 1993-11-12 Glaxo Lab Sa Compositions à activité agoniste des récepteurs analogues à 5HT1 sélective.
FR2691630A1 (fr) * 1992-05-28 1993-12-03 Glaxo Lab Sa Composition pharmaceutique, en particulier pour l'administration orale, contenant, comme ingrédient actif, un agoniste sélectif des récepteurs de type 5HT1.
WO1993024116A1 (fr) * 1992-05-28 1993-12-09 Glaxo Canada Inc. Compositions pharmaceutiques comprenant des agonistes des recepteurs 5-ht1 et des stimulateurs d'absorption
EP0574624A1 (fr) * 1992-06-17 1993-12-22 Laboratoires Glaxo Sa Compositions pharmaceutiques
WO1994003162A1 (fr) * 1992-07-31 1994-02-17 Glaxo Group Limited Medicaments de traitement ou de prevention de la pression intraoculaire elevee
US5409941A (en) * 1992-02-03 1995-04-25 Pfizer Inc. 5-heteroyl indole derivatives
WO1995014004A1 (fr) * 1993-11-19 1995-05-26 Pierre Fabre Medicament Arylpiperazines derivees d'indole comme ligands pour les recepteurs 5 ht1-like 5 ht1b et 5 ht1d

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252749A (en) * 1991-09-25 1993-10-12 Elf Sanofi Ethers of thienocyclopentanone oximes, their preparation and pharmaceutical compositions containing them
US5409941A (en) * 1992-02-03 1995-04-25 Pfizer Inc. 5-heteroyl indole derivatives
FR2690847A1 (fr) * 1992-05-07 1993-11-12 Glaxo Lab Sa Compositions à activité agoniste des récepteurs analogues à 5HT1 sélective.
FR2691630A1 (fr) * 1992-05-28 1993-12-03 Glaxo Lab Sa Composition pharmaceutique, en particulier pour l'administration orale, contenant, comme ingrédient actif, un agoniste sélectif des récepteurs de type 5HT1.
WO1993024116A1 (fr) * 1992-05-28 1993-12-09 Glaxo Canada Inc. Compositions pharmaceutiques comprenant des agonistes des recepteurs 5-ht1 et des stimulateurs d'absorption
EP0574624A1 (fr) * 1992-06-17 1993-12-22 Laboratoires Glaxo Sa Compositions pharmaceutiques
WO1994003162A1 (fr) * 1992-07-31 1994-02-17 Glaxo Group Limited Medicaments de traitement ou de prevention de la pression intraoculaire elevee
WO1995014004A1 (fr) * 1993-11-19 1995-05-26 Pierre Fabre Medicament Arylpiperazines derivees d'indole comme ligands pour les recepteurs 5 ht1-like 5 ht1b et 5 ht1d

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999022730A1 (fr) * 1997-10-31 1999-05-14 Vanguard Medica Limited Utilisation de (+)-6-carboxamido-3-methylamino-1,2,3,4-tetrahydrocarbazole pour le traitement de l'hyperalgie
EP1410798A2 (fr) * 1999-01-08 2004-04-21 Maxim Pharmaceuticals, Inc. Traitement et prévention des dommages cellulaires induits par des métabolites réactives d'oxygène
EP1410798A3 (fr) * 1999-01-08 2004-10-13 Maxim Pharmaceuticals, Inc. Traitement et prevention des dommages cellulaires induits par des metabolites reactives d'oxygene
WO2000074649A2 (fr) * 1999-06-03 2000-12-14 Maxim Pharmaceuticals, Inc. Compositions ophtalmiques a base d'histamine et leurs utilisations
WO2000074649A3 (fr) * 1999-06-03 2002-01-17 Maxim Pharm Inc Compositions ophtalmiques a base d'histamine et leurs utilisations
US6531120B2 (en) 1999-06-03 2003-03-11 Maxim Pharmaceuticals, Inc. Ophthalmic histamine compositions and uses thereof
WO2001015677A2 (fr) * 1999-08-31 2001-03-08 Alcon Laboratories, Inc. Utilisation d'agonistes de 5-ht1b/1d pour le traitement des douleurs oculaires
WO2001015677A3 (fr) * 1999-08-31 2002-03-28 Alcon Lab Inc Utilisation d'agonistes de 5-ht1b/1d pour le traitement des douleurs oculaires
EP1536819A2 (fr) * 2002-03-29 2005-06-08 Maxim Pharmaceuticals, Inc. Utilisation de la production de rom et d'inhibiteurs de liberation pour traiter et prevenir des dommages intraoculaires
EP1536819A4 (fr) * 2002-03-29 2007-10-17 Maxim Pharm Inc Utilisation de la production de rom et d'inhibiteurs de liberation pour traiter et prevenir des dommages intraoculaires

Also Published As

Publication number Publication date
AU2434297A (en) 1997-12-09

Similar Documents

Publication Publication Date Title
JP2009067806A (ja) 眼の痛みを治療するためのκオピオイド・アゴニストの局所使用
KR100452715B1 (ko) 녹내장및안구국소빈혈을치료하기위한특정이소퀴놀린술포닐화합물의용도
AU754588B2 (en) Cholinergic agents in the treatment of presbyopia
CA2502437C (fr) Procede et composition contenant du latanoprost destines au traitement de l'hypertension oculaire et d'un glaucome
US5459133A (en) Methods and products for treating presbyopia
KR100435611B1 (ko) 에피나스틴을포함하는동통치료용약제학적조성물
JPS63313728A (ja) プロスタグランジンとアドレナリン性遮断剤との組合せからなる眼圧降下用組成物
WO1992007563A1 (fr) Traitement d'hypertension oculaire au moyen d'inhibiteurs calciques classe i
AU2011282683B2 (en) Preservative free brimonidine and timolol solutions
KR20140056280A (ko) 비마토프로스트 및 브리모니딘의 고정된 용량 조합
US5686488A (en) Polyethoxylated castor oil products as anti-inflammatory agents
KR102657652B1 (ko) 눈 통증의 예방 및 치료를 위한 아미노포스핀산 유도체
WO1995020378A1 (fr) Compositions de traitement du glaucome comprenant de la pilocarpine et un beta-bloquant
WO1997044062A1 (fr) Utilisation d'agonistes de 5-ht1b/1d dans le traitement de douleurs oculaires
EP1447094A9 (fr) Remedes contre le prurit
US9187468B2 (en) Topical ocular analgesic agents
JP2007517885A (ja) 眼に投与するためのメマンチンおよびポリアニオン性ポリマーを含む組成物
EP1267849B1 (fr) Substances diminuant la reapparition de l'usage de drogues
EP3737378B1 (fr) Collyre palonosétron destiné au traitement ou la prévention de nausées et vomissements
WO2002040028A1 (fr) Gouttes pour les yeux en gel antibacterien
WO2003063879A1 (fr) Remedes contre le glaucome contenant de la bunazosine et des prostaglandines
JPH11147825A (ja) 粘膜吸収性の向上方法及び粘膜外用剤
JPH04247036A (ja) 縮瞳をおこすことなく眼圧を下げる治療方法
CN102264344A (zh) 递送有效浓度的活性剂至眼睛后段的局部眼用溶液组合物
WO2000043015A1 (fr) Gouttes ophtalmologiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA CN JP KR MX US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97542340

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase